Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-08-24
1999-11-30
Reamer, James H.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3144
Patent
active
059943637
ABSTRACT:
Symptoms of Parkinson's disease and psychogenic male erectile dysfunction (MED) can be ameliorated through the use of apomorphine. The adverse side effects of apomorphine administration, such as nausea, vomiting, yawning, and cardiovascular effects, can be significantly reduced by a dose escalating method of acclimatization. An initial dose of apomorphine is administered to the patient, and subsequently increased over a period of time until a final apomorphine dose in excess of a desired therapeutic dose has been received by the patient. Thereafter a therapeutic dose of apomorphine, less than the final apomorphine dose, is administered to the patient with attendant reduced side effects.
REFERENCES:
patent: 2818855 (1958-01-01), Miller
patent: 3976780 (1976-08-01), Thominet
patent: 4127118 (1978-11-01), Latorre
patent: 4521421 (1985-06-01), Foreman
patent: 4543256 (1985-09-01), Neumeyer
patent: 4569940 (1986-02-01), Watts
patent: 4624965 (1986-11-01), Wenig
patent: 4687773 (1987-08-01), Neumeyer et al.
patent: 4749686 (1988-06-01), Hintze
patent: 4749700 (1988-06-01), Wenig
patent: 4772459 (1988-09-01), Sun et al.
patent: 4801587 (1989-01-01), Voss
patent: 5102887 (1992-04-01), Goldberg
patent: 5242391 (1993-09-01), Place et al.
patent: 5270323 (1993-12-01), Milne, Jr. et al.
patent: 5310561 (1994-05-01), Jao et al.
Danjou et al., Br. J. Clin. Pharmac. 26:733-739 (1988).
Gancher et al., Ann. Neurol. 26:232-238 (1989).
Segraves, Arch. Gen. Psych. 46:275-284 (1989).
Heaton et al., J. Urology 145:1099-1102 (1991).
Montastruc et al., Clin. Neuropharmacology 14(5):432-437 (1991).
Durif et al., Eur. J. Clin. Pharmacology 41:493-494 (1991).
Gancher et al., Movement Disorders 6(3):212-216 (1991).
Segraves et al., J. Urology 145:1174-1175 (1991).
Segraves, R.T., Dopamine agonists and their effect on the human penile erectile response, pp. 225-229 in Bancroft, J., editor, The Pharmacology of Sexual Function and Dysfunction, Excerpta Medica, Amsterdam (1995).
El-Rashidy Ragab
Ronsen Bruce
Pentech Pharmaceuticals, Inc.
Reamer James H.
LandOfFree
Amelioration of apomorphine adverse effects does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amelioration of apomorphine adverse effects, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amelioration of apomorphine adverse effects will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1672978